Eagle Pharmaceuticals Inc Investor Day Transcript
Good morning, everyone. Thank you for joining us, both here at the Palace Hotel in beautiful New York, and those on the live webcast, that couldn't be with us here today.
Before we get started, I'd like to refer to our forward-looking statements. If you can all take a moment to read them, please. Thank you.
During the next few hours, we will focus on the scientific and clinical rationale driving Eagle's hospital-based pipeline and commercial products and lay out for you Eagle's value proposition for patients, the health care system and shareholders.
We will showcase the strength of these development programs as well as our recently acquired approved assets, including Enalare's ENA-001, an agnostic respiratory stimulant being developed by Enalare for the potential treatment of postoperative respiratory depression, community drug overdose and Apnea of Prematurity.
As a reminder, we acquired approximately a 14% equity stake in Enalare earlier this year and have an option to purchase
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |